Drutz David 4
4 · Altimmune, Inc. · Filed Aug 20, 2024
Insider Transaction Report
Form 4
Drutz David
Director
Transactions
- Sale
Common Stock, par value $0.0001
2024-08-19$6.93/sh−7,827$54,241→ 41,958 total(indirect: See Footnote) - Sale
Common Stock, par value $0.0001
2024-08-19$6.88/sh−8,184$56,306→ 55,524 total(indirect: See Footnote) - Exercise/Conversion
Stock Options (option to buy)
2024-08-19−21,750→ 4,350 totalExercise: $2.50Exp: 2033-09-28→ Common Stock, par value $0.0001 (21,750 underlying) - Exercise/Conversion
Common Stock, par value $0.0001
2024-08-19$2.60/sh+20,000$52,000→ 49,785 total(indirect: See Footnote) - Exercise/Conversion
Common Stock, par value $0.0001
2024-08-19$2.50/sh+21,750$54,375→ 63,708 total(indirect: See Footnote) - Exercise/Conversion
Stock Options (option to buy)
2024-08-19−20,000→ 0 totalExercise: $2.60Exp: 2029-01-02→ Common Stock, par value $0.0001 (20,000 underlying)
Footnotes (5)
- [F1]Shares received upon exercise were immediately transferred to Pacific Biopharma Associates, LLC.
- [F2]Represents Common Stock held by Pacific Biopharma Associates, LLC, of which the reporting person is the President.
- [F3]This sale represents shares sold to cover the exercise price.
- [F4]The shares underlying the option became vested and exercisable in two equal installments on February 28, 2019 and August 30, 2019, in each case, generally subject to the reporting person's continued service through the applicable vesting date.
- [F5]The shares underlying the option became vested and exercisable in substantially equal monthly installments over the 12 months following September 28, 2023, subject to the reporting person's continued service through the applicable vesting date.